{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T09:32:41Z","timestamp":1795167161932,"version":"4.10.3"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":20,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.cmi.2026.09.018","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T15:25:15Z","timestamp":1790004315000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical and regulatory acceptability of hierarchical composite endpoints in infectious disease clinical trials"],"prefix":"10.1016","author":[{"given":"Amos J.","family":"de Jong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daphne S.A.","family":"Bennink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selina","family":"Ehrenzeller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Speich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Briel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean W.X.","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna M.G.","family":"Pasmooij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein P.M.","family":"Hensgens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2026.09.018_bib1","doi-asserted-by":"crossref","first-page":"e319","DOI":"10.1093\/cid\/ciaf314","article-title":"Making sense of hierarchical composite endpoints in randomized clinical trials\u2013A primer for infectious disease clinicians and researchers","volume":"81","author":"Ong","year":"2025","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2026.09.018_bib2","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1093\/eurheartj\/ehaa665","article-title":"The win ratio approach for composite endpoints: Practical guidance based on previous experience","volume":"41","author":"Redfors","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cmi.2026.09.018_bib3","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1093\/cid\/civ495","article-title":"Desirability of outcome ranking (DOOR) and response adjusted for duration of antibiotic risk (RADAR)","volume":"61","author":"Evans","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2026.09.018_bib4","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.cmi.2023.05.003","article-title":"Unlocking the DOOR\u2014How to design, apply, analyse, and interpret desirability of outcome ranking endpoints in infectious diseases clinical trials","volume":"29","author":"Ong","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2026.09.018_bib5","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s43441-022-00420-1","article-title":"Design and analysis of studies based on hierarchical composite endpoints: Insights from the DARE-19 trial","volume":"56","author":"Gasparyan","year":"2022","journal-title":"Ther Innov Regul Sci"},{"key":"10.1016\/j.cmi.2026.09.018_bib6","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1093\/cid\/ciy766","article-title":"Good studies evaluate the disease while great studies evaluate the patient: Development and application of a desirability of outcome ranking endpoint for staphylococcus aureus bloodstream infection","volume":"68","author":"Doernberg","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2026.09.018_bib7","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2026.25935","article-title":"Randomized trials using a hierarchical composite primary endpoint: A scoping review","volume":"9","author":"Ehrenzeller","year":"2026","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.cmi.2026.09.018_bib8","doi-asserted-by":"crossref","first-page":"e1157","DOI":"10.1093\/cid\/ciac692","article-title":"Improving traditional registrational trial end points: Development and application of a desirability of outcome ranking end point for complicated urinary tract infection clinical trials","volume":"76","author":"Howard-Anderson","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2026.09.018_bib9","doi-asserted-by":"crossref","first-page":"221","DOI":"10.5194\/jbji-7-221-2022","article-title":"A desirability of outcome ranking (DOOR) for periprosthetic joint infection\u2014A Delphi analysis","volume":"7","author":"Johns","year":"2022","journal-title":"J Bone Jt Infect"},{"key":"10.1016\/j.cmi.2026.09.018_bib10","doi-asserted-by":"crossref","first-page":"e1166","DOI":"10.1093\/cid\/ciac778","article-title":"Opening a DOOR for pivotal studies: An example for complicated urinary tract infections","volume":"76","author":"Rodr\u00edguez-Ba\u00f1o","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2026.09.018_bib11","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/intqhc\/mzm042","article-title":"Consolidated criteria for reporting qualitative research (COREQ): A 32-item checklist for interviews and focus groups","volume":"19","author":"Tong","year":"2007","journal-title":"Int J Qual Health Care"},{"key":"10.1016\/j.cmi.2026.09.018_bib12","article-title":"Study protocol","author":"de Jong","year":"2025","journal-title":"HCE-ACCEPT"},{"key":"10.1016\/j.cmi.2026.09.018_bib13","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/j.jacc.2023.06.047","article-title":"Generalized pairwise comparisons to assess treatment effects: JACC review topic of the week","volume":"82","author":"Verbeeck","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cmi.2026.09.018_bib14","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1001\/jamapediatrics.2021.5547","article-title":"Short-vs standard-course outpatient antibiotic therapy for community-acquired pneumonia in children: The SCOUT-CAP randomized clinical trial","volume":"176","author":"Williams","year":"2022","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.cmi.2026.09.018_bib15","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1056\/NEJMoa2100433","article-title":"Interleukin-6 receptor antagonists in critically ill patients with Covid-19","volume":"384","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2026.09.018_bib16","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1191\/1478088706qp063oa","article-title":"Using thematic analysis in psychology","volume":"3","author":"Braun","year":"2006","journal-title":"Qual Res Psychol"},{"key":"10.1016\/j.cmi.2026.09.018_bib17","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/s12874-021-01359-x","article-title":"Investigator initiated trials versus industry sponsored trials\u2014Translation of randomized controlled trials into clinical practice (IMPACT)","volume":"21","author":"Bl\u00fcmle","year":"2021","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.cmi.2026.09.018_bib18","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofag320","article-title":"Development and application of a desirability of outcome ranking (DOOR) endpoint for acute bacterial skin and skin structure infections","volume":"13","author":"Howard-Anderson","year":"2026","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2026.09.018_bib19","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/cid\/ciad239","article-title":"Exploration of a potential desirability of outcome ranking endpoint for complicated intra-abdominal infections using 9 registrational trials for antibacterial drugs","volume":"77","author":"Kinamon","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2026.09.018_bib20","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/cid\/ciae163","article-title":"Exploration of a potential door endpoint for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia using six registrational trials for antibacterial drugs","volume":"79","author":"Kinamon","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2026.09.018_bib26","author":"Randomized"},{"key":"10.1016\/j.cmi.2026.09.018_bib27","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1093\/cid\/ciz093","article-title":"Elaboration of consensus clinical endpoints to evaluate antimicrobial treatment efficacy in future hospital-acquired\/ventilator-associated bacterial pneumonia clinical trials","volume":"69","author":"Weiss","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2026.09.018_bib28","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1001\/jama.2025.12543","article-title":"Dalbavancin for treatment of Staphylococcus aureus bacteremia: The DOTS randomized clinical trial","volume":"334","author":"Turner","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2026.09.018_bib29","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0140-6736(26)00761-0","article-title":"Benzylpenicillin versus flucloxacillin or cloxacillin for the treatment of penicillin-susceptible Staphylococcus aureus bacteraemia (SNAP): An international, multicentre, open-label, non-inferiority randomised controlled trial","volume":"408","year":"2026","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2026.09.018_bib30","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1056\/NEJMoa2506905","article-title":"Cefazolin for methicillin-susceptible Staphylococcus aureus bacteremia","volume":"394","author":"Lee","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2026.09.018_bib31","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2026-118509","article-title":"Linezolid in addition to standard antibiotic treatment for Staphylococcus aureus bacteraemia: Study protocol for a randomised, placebo-controlled trial","volume":"16","author":"Rose","year":"2026","journal-title":"BMJ Open"},{"key":"10.1016\/j.cmi.2026.09.018_bib32","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa2304968","article-title":"Ferric carboxymaltose in heart failure with iron deficiency","volume":"389","author":"Mentz","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2026.09.018_bib33","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1002\/sim.8967","article-title":"Win odds: An adaptation of the win ratio to include ties","volume":"40","author":"Brunner","year":"2021","journal-title":"Stat Med"},{"key":"10.1016\/j.cmi.2026.09.018_bib34","doi-asserted-by":"crossref","first-page":"4684","DOI":"10.1093\/eurheartj\/ehae647","article-title":"The win ratio in cardiology trials: Lessons learnt, new developments, and wise future use","volume":"45","author":"Pocock","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cmi.2026.09.018_bib35","series-title":"Points to consider on multiplicity issues in clinical trials","year":"2002"},{"key":"10.1016\/j.cmi.2026.09.018_bib36","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/jama.2025.25686","article-title":"Win ratio method for hierarchical composite outcomes in randomized clinical trials","volume":"335","author":"Cunningham","year":"2026","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2026.09.018_bib37","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDctw2500029","article-title":"Evaluating noninferiority in clinical trials with a hierarchical end point","volume":"5","author":"Gregson","year":"2026","journal-title":"NEJM Evid"},{"key":"10.1016\/j.cmi.2026.09.018_bib38","series-title":"Guideline on the clinical investigation of medicinal products in the treatment of patients with acute respiratory distress syndrome","year":"2025"},{"key":"10.1016\/j.cmi.2026.09.018_bib39","series-title":"Guideline on the clinical evaluation of medicinal products indicated for the prophylaxis or treatment of respiratory syncytial virus (RSV) disease","year":"2018"},{"key":"10.1016\/j.cmi.2026.09.018_bib40","series-title":"Guideline on influenza vaccines: Non-clinical and clinical module","year":"2016"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X26005343?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X26005343?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T11:33:29Z","timestamp":1791632009000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X26005343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":35,"alternative-id":["S1198743X26005343"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2026.09.018","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical and regulatory acceptability of hierarchical composite endpoints in infectious disease clinical trials","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2026.09.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.","name":"copyright","label":"Copyright"}]}}